Search

Displaying results 6411 - 6420 of 10000 in total
  1. Drug

    Echinomycin

    go.drugbank.com/drugs/DB15582
    Experimental

    Echinomycin is a cytotoxic polypeptide quinoxaline antibiotic isolated from _Streptomyces echinatus_ that binds to DNA and inhibits RNA synthesis.

    Synonyms: Quinomycin A
  2. Drug

    ORG-31710

    go.drugbank.com/drugs/DB15585
    Experimental

    ORG-31710 is a progestational hormone antagonist.

  3. Drug

    Fennel

    go.drugbank.com/drugs/DB15615
    Approved

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors
  4. Drug

    Fluzoparib

    go.drugbank.com/drugs/DB15637
    Investigational

    Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

  5. Drug

    Gusacitinib

    go.drugbank.com/drugs/DB15670
    Investigational

    Gusacitinib is under investigation in clinical trial NCT02550678 (A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma).

  6. Drug

    Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15682
    ApprovedInvestigational

  7. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection. … BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.

  8. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech. … [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

  9. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  10. Drug

    IL15-NK Cell

    go.drugbank.com/drugs/DB15725
    Investigational

    In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.